ProMIS Neurosciences Inc. - Asset Resilience Ratio
ProMIS Neurosciences Inc. (PMN) has an Asset Resilience Ratio of 0.15% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ProMIS Neurosciences Inc. strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how ProMIS Neurosciences Inc.'s Asset Resilience Ratio has changed over time. See debt-free asset ratio of ProMIS Neurosciences Inc. to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down ProMIS Neurosciences Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PMN stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $33.05K | 0.15% |
| Total Liquid Assets | $33.05K | 0.15% |
Asset Resilience Insights
- Limited Liquidity: ProMIS Neurosciences Inc. maintains only 0.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ProMIS Neurosciences Inc. Industry Peers by Asset Resilience Ratio
Compare ProMIS Neurosciences Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for ProMIS Neurosciences Inc. (2005–2024)
The table below shows the annual Asset Resilience Ratio data for ProMIS Neurosciences Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.17% | $33.05K | $18.91 Million | -0.06pp |
| 2023-12-31 | 0.24% | $32.36K | $13.62 Million | -0.40pp |
| 2022-12-31 | 0.63% | $59.46K | $9.38 Million | +0.41pp |
| 2021-12-31 | 0.23% | $50.69K | $22.44 Million | -5.31pp |
| 2020-12-31 | 5.54% | $76.72K | $1.38 Million | +3.52pp |
| 2019-12-31 | 2.02% | $41.83K | $2.07 Million | +0.61pp |
| 2018-12-31 | 1.40% | $41.62K | $2.97 Million | -0.50pp |
| 2017-12-31 | 1.91% | $41.41K | $2.17 Million | -1.66pp |
| 2015-12-31 | 3.56% | $41.00K | $1.15 Million | -73.35pp |
| 2009-12-31 | 76.91% | $4.08 Million | $5.31 Million | +1.49pp |
| 2008-12-31 | 75.42% | $3.30 Million | $4.37 Million | +10.68pp |
| 2007-12-31 | 64.74% | $6.28 Million | $9.71 Million | -18.01pp |
| 2006-12-31 | 82.75% | $10.57 Million | $12.77 Million | -11.92pp |
| 2005-12-31 | 94.67% | $4.51 Million | $4.76 Million | -- |
About ProMIS Neurosciences Inc.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product c… Read more